Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial).

Trial Profile

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial).

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2015

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms REST
  • Most Recent Events

    • 25 Apr 2015 Results of reanalysis showing significant changes presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top